United Therapeutics Corporation Business Combination, Acquisition Related Costs
United Therapeutics Corporation (UTHR) reported Business Combination, Acquisition Related Costs of $5.40 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2019-02-27
- United Therapeutics Corporation business combination, acquisition related costs for the quarter ending 2018-12-31 was $400.00K.
- United Therapeutics Corporation business combination, acquisition related costs for the quarter ending 2018-09-30 was $2.50M.
- United Therapeutics Corporation business combination, acquisition related costs for fiscal 2018 was $5.40M.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 6 month | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|---|
| 2018-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $2.90M derived: sum of 2 quarters · filed 2019-02-27 | $5.40M 10-K · filed 2019-02-27 | |
| 2018-09-30 | $2.50M 10-Q · filed 2018-10-31 | $5.00M 10-Q · filed 2018-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |